A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Ponatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2016 Time frame of the primary end point changed from 24-36 months to 2-4 months, according to ClinicalTrials.gov record.
- 16 Mar 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.